Adalvo Is A Global Pharmaceutical Company Founded In 2018Recognized As A Leading B2B Player In The Industrythe Company Is Dedicated To Improving Patientslives Through A Strong Commitment To Excellence And A Purpose Driven Cultureadalvo Operates A Smart Collaboration Network That Enhances Its Strategic Choices And Drives Positive Change In Healthcare The Company Offers A Robust Portfolio Of Pharmaceutical Productsincluding Over 120 Differentiated Medicinespeptidesbiosimilarsand Oncology Productsadalvo Specializes In The Commercialization Of These Productsfostering Partnerships With Other Pharmaceutical Companies And Healthcare Organizations To Expand Its Market Reachits Structured Launch Management System Ensures Efficient Introduction Of New Products Into Various Marketswhere It Serves Partners And Patients Across More Than 140 Countries Adalvo Has Experienced Significant Growthachieving A Compound Annual Growth Rate Of Approximately 60In Ebitdathe Company Was Acquired By Aztiq In 2024Further Positioning It For Continued Success In The Pharmaceutical Sector
Germany
